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Nuclear receptors (NR) impact a myriad of physiological processes including homeostasis, reproduction,
development, and metabolism. NRs are regulated by post-translational modifications (PTM) that markedly
impact receptor function. Recent studies have identified NR PTMs that are involved in the onset and progression
of human diseases, including cancer.The majority of evidence linking NR PTMs with disease has been
demonstrated for phosphorylation, acetylation and sumoylation of androgen receptor (AR), estrogen receptor
α (ERα), glucocorticoid receptor (GR) and peroxisome proliferator activated receptor γ (PPARγ). Phosphorylation
of AR has been associated with hormone refractory prostate cancer and decreased disease-specific survival.
AR acetylation and sumoylation increased growth of prostate cancer tumor models. AR phosphorylation
reduced the toxicity of the expanded polyglutamine AR in Kennedy’s Disease as a consequence of reduced
ligand binding. A comprehensive evaluation of ERα phosphorylation in breast cancer revealed several sites
associated with better clinical outcome to tamoxifen therapy, whereas other phosphorylation sites were
associated with poorer clinical outcome. ERα acetylation and sumoylation may also have predictive value
for breast cancer. GR phosphorylation and acetylation impact GR responsiveness to glucocorticoids that are
used as anti-inflammatory drugs. PPARγ phosphorylation can regulate the balance between growth and
differentiation in adipose tissue that is linked to obesity and insulin resistance. Sumoylation of PPARγ is
linked to repression of inflammatory genes important in patients with inflammatory diseases. NR PTMs provide
an additional measure of NR function that can be used as both biomarkers of disease progression, and
predictive markers for patient response to NR-directed treatments.
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Introduction
Nuclear receptor (NR) function is regulated by
post-translational modifications (PTM) including
phosphorylation, acetylation, sumoylation, methylation,
myristylation, nitration, ADP-ribosylation, and
isoprenylation.These PTMs can be further divided into
two categories: 1) reversible modifications that function
by either addition or removal of functional chemical groups
(i.e., phosphate, acetyl) on specific amino acid residues
of target proteins [serine (S), tyrosine (Y), threonine (T),
lysine (K)]; or 2) modifications involving addition of other
proteins or polypeptides (e.g., sumoylation and
ubiquitination).
Recently, many investigations have provided direct
evidence for NR PTM in the pathophysiological
progression of many diseases including cancers,
diabetes, and obesity, among others.The majority of
evidence linking NR PTMs with disease has been
demonstrated for phosphorylation, sumoylation,
ubiquitination and acetylation in the androgen receptor
(AR), estrogen receptor (ER), glucocorticoid receptor
(GR) and the peroxisome proliferator activated receptor
γ (PPARγ).This report will be limited to a review of PTMs
in ER, AR, GR and PPARγ and association with disease.
Androgen receptor
AR phosphorylation and prostate cancer
Advanced prostate cancer treatment has relied on
hormone-deprivation therapy for the past 50 years.
Response rates are initially high (70–80%); however,
almost all patients relapse and develop
hormone-refractory prostate cancer (HRPC), resulting in
increased morbidity and death [McCall et al., 2008].
The majority of studies that demonstrate a relationship
between AR phosphorylation and prostate cancer
development have focused on the PI3K/Akt pathway
(Figure 1). Studies in vitro demonstrate that the PI3K/Akt
pathway is upregulated in HRPC and can result in
phosphorylation of the AR. Akt is activated when
phosphorylated at threonine 308 (T308), and
subsequently serine 473 (S473), and these
phosphorylations may play a similar role in the
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vitro studies have demonstrated that Akt can
phosphorylate AR at serine residues S210 and S790,
resulting in modulation of AR transcriptional activity [Lin
et al., 2003; Lin et al., 2001].
Studies have shown that pAkt S473 is expressed in PIN
(Prostatic Intraepithelial Neoplasia) and invasive prostate
cancer with staining intensity positively correlated with
PSA levels and Gleason grades [Altomare and Testa,
2005; Ghosh et al., 2003; Majumder and Sellers, 2005].
Increased phospho-Akt at S473 (pAkt S473) and
phospho-AR S210 (pAR S210) was associated with
decreased disease-specific survival [McCall et al., 2008].
In addition, phosphorylation of Akt at S473 and AR at
S210 strongly correlated with HRPC [McCall et al., 2008]
and HRPCs expressed significantly higher levels of pAR
S210 compared to hormone-sensitive tumors [McCall et
al., 2008].
Since upregulation of the PI3K/Akt pathway is associated
with phosphorylation of AR during development of HRPC,
Akt inhibitors are being developed as targeted
therapeutics. Future clinical studies will determine whether
activated Akt and/or phosphorylation of AR at S210 may
be developed as predictive biomarkers for selecting
patients who would respond to Akt inhibitors.
Figure 1.  Phosphorylation sites in nuclear receptors. Nuclear
receptor function is regulated in large part by post-translational
modification, including phosphorylation. Phosphorylation occurs on serine
(S), threonine (T) and tyrosine (Y) residues. AF-1- Activation Function-1;
DBD- DNA Binding Domain; AF-2- Activation Function-2; LBD- Ligand
Binding Domain.
AR phosphorylation in spinal and bulbar
muscular atrophy
Spinal and bulbar muscular atrophy (SBMA; also known
as Kennedy’s Disease) is a progressive
neurodegenerative disease characterized by muscle
weakness, muscle atrophy, and fasciculations. SBMA is
caused by an abnormally high number of CAG
trinucleotide repeats that encode for a stretch of
uninterrupted polyglutamine amino acids in the AR known
as a polyglutamine tract or polyQ tract [Mukherjee et al.,
2009].
Studies in transgenic SBMA mouse models demonstrated
that the reduction of serum androgen levels rescues the
motor dysfunction and nuclear accumulation of mutant
androgen receptors and improves survival of transgenic
SBMA mice [Chevalier-Larsen et al., 2004; Katsuno et
al., 2003a; Katsuno et al., 2003b].Therefore, decreasing
the effect of ligand on the AR could reduce disease
progression. Furthermore, Palazzolo et al. demonstrated
that in motor neuron-derived cells, phosphorylation of AR
at the Akt consensus sites S215 and S792 reduced
ligand-dependent nuclear translocation and toxicity of the
expanded polyQ AR, as a consequence of reduced ligand
binding [Palazzolo et al., 2007].
Leuprorelin, a luteinizing hormone–releasing hormone
agonist that reduces testosterone release from the testis
and inhibits nuclear accumulation of mutant AR, rescued
motor dysfunction in male transgenic mice carrying
full-length mutant human AR with an expanded polyQ
tract [Katsuno et al., 2003]. Phase II clinical trials of
leuprorelin suggested that androgen deprivation inhibited
nuclear accumulation and/or stabilization of mutant AR
in the motor neurons of the spinal cord and brainstem
[Banno et al., 2009].
It is important to note that the phosphorylation sites in
prostate cancer and SBMA are not different. AR may
differ in length because of the polyQ and glycine repeats,
but the most common size of AR is 919 amino acids.The
Akt consensus phosphorylation sites of AR with 919
amino acid residues are S213 and S791 (Figure 1); these
same sites were reported as S210 and S790 by McCall
et al. [McCall et al., 2008] and S215 and S792 by
Palazzolo et al. [Palazzolo et al., 2007], although the sites
are not different.The discrepancies in the phosphorylation
sites mentioned in prostate cancer and SBMA might be
due to the fact that AR differs in their length because of
heterogeneity of the polyQ and glycine tracts.
AR sumoylation in prostate cancer and SBMA
Sumoylation, the process of covalently attaching small
ubiquitin-like modifiers to proteins, functions to regulate
protein stability, protein–protein interactions,
transcriptional activity, and subcellular localization [Hay,
2005; Seeler and Dejean, 2003].The majority of identified
SUMO substrates are active in transcription, RNA
processing, DNA repair and chromatin remodeling
(reviewed in [Karamouzis et al., 2008]). Androgen
receptor was the first NR shown to be sumoylated
[Poukka et al., 2000].
Sumoylation is mediated by activating, conjugating and
ligating enzymes, and is reversed by a family of
SUMO-specific proteases (SENPs); one member in
particular, SENP1, was recently identified as a gene
required for proliferation and survival of normal and
prostate cancer cells [Schlabach et al., 2008]. Expression
of SENP1 in prostate cancer cells increased the
transcription activity of endogenous AR. Silencing of
SENP1 attenuated the expression of several AR target
genes and inhibited the androgen-stimulated growth of
LNCaP cells (androgen-dependent prostate cancer cells)
www.nursa.org  NRS  | 2012 |  Vol. 10 |  DOI: 10.1621/nrs.10001 | Page 2 of 13
Review PTMs of NRs and human disease[Bawa-Khalfe et al., 2007; Kaikkonen et al., 2009].
Additionally, SENP1 was overexpressed in human
prostate cancer specimens [Cheng et al., 2006].
Transgenic mice overexpressing SENP1 in the prostate
gland also developed Prostatic Intraepithelial Neoplasia
(PIN) at an early age [Cheng et al., 2006].
Taken together, this suggests that SENP1 plays an
important role in not only proliferation of prostate cancer
cells, but in onset, as well [Bawa-Khalfe et al., 2007].
These data suggest the SUMO modification pathway as
a potential target for prostate cancer therapy.
The two sumoylation sites of AR in human are K386 and
K520 (Figure 2A). Cell culture studies have shown that
sumoylation could reduce the formation of polyQ
expanded AR aggregates without affecting the levels of
the receptor, and the anti-aggregation effect by
sumoylation was not dependent upon AR transcriptional
activity [Mukherjee et al., 2009]. Chan et al. [Chan et al.,
2002] reported that the Drosophila SBMA model with
mutant polyQ AR exhibited a neurodegenerative
phenotype.
Figure 2.  Sumoylation and ubiquitination of the androgen receptor
are involved in spinal and bulbar muscular atrophy. Spinal and
bulbar muscular atrophy is caused by an abnormally high number of CAG
trinucleotide repeats that encode for a stretch of uninterrupted
polyglutamine amino acids in the AR known as a polyglutamine tract or
polyQ tract. (A) Sumoylation of the androgen receptor has been shown
to reduce aggregates of polyQ and occurs at lysine residues 386 and
520. (B) Overexpression of carboxyl terminus of Hsp70-interacting protein
(CHIP), an ubiquitin E3 ligase, leads to ubiquitination of mutant AR,
providing protection from SBMA.
Furthermore, expression of a catalytic-deficient mutant
of the SUMO-1 activating enzyme Uba2 further
exacerbated the polyQ AR-induced neurodegeneration
[Chan et al., 2002; Dorval and Fraser, 2007]. In contrast,
in other diseases associated with polyQ expanded regions
in proteins such as the protein huntingtin in Huntington's
disease, it has been suggested that sumoylation
intensifies the polyQ huntingtin-induced
neurodegeneration in the Drosophila model [Steffan et
al., 2004].
Taken together, sumoylation might have either beneficial
or harmful effects, depending on the polyQ protein, and
further studies using SBMA double transgenic mice with
mutation at the sumoylation site of AR might provide more
insight into the role of sumoylation in SBMA.
AR ubiquitination and SBMA
NRs are well known substrates for ubiquitination [Adachi
et al., 2007], which is the covalent attachment of a
peptide, ubiquitin, to lysine residues of a substrate protein.
Similar to sumoylation, ubiquitination requires an
activating enzyme (E1), a conjugating enzyme (E2), and
an E3 ubiquitin ligase (Figure 2B). Although most NRs
are ubiquitinated, discussion here will be limited to a
review of ubiquitination of AR, ERα and PPARγ, since
the ubiquitination of these NRs were clearly linked to
human diseases.
Carboxyl terminus of Hsp70-interacting protein (CHIP) is
E2 ubiquitin ligase that interacts with heat shock proteins
and chaperones to degrade toxic and misfolded proteins
[McDonough and Patterson, 2003]. Double transgenic
mice which overexpressed CHIP and mutant AR
demonstrated that mutant AR protein was ubiquitinated
and degraded by CHIP and the proteosomal system,
which resulted in protection of mice from SBMA [Adachi
et al., 2007]. Moreover, other neurodegenerative diseases
that are caused by polyQ expansion of proteins ataxin-1
(type 1 spinocerebellar ataxia) and Huntingtin were also
benefited by ubiquitination and proteosomal degradation
[Al-Ramahi et al., 2006; Jana et al., 2005].
Overall, ubiquitination has been shown to play a vital role
in protecting neuronal cells against the toxic properties
of polyQ expanded proteins.
AR acetylation and prostate cancer
Acetylation of AR is in response to physiological stimuli
including DHT (dihydrotestosterone) and bombesin
enhanced AR transactivation function at a subset of target
promoters [Fu et al., 2004], in particular cell cycle control
genes that induce cellular proliferation [Gong et al., 2006;
Popov et al., 2007]. Direct acetylation of AR at the highly
conserved KXKK/RXKK lysine motif (lysine 630, 632 and
633), is mediated by coactivators p300, P/CAF and TIP60
(Tat-interactive protein) that possess intrinsic histone
acetyltransferase (HAT) activity (Figure 3A) [Fu et al.,
2003; Fu et al., 2000; Gaughan et al., 2002].
The proliferation of prostate cancer cell lines stably
expressing the AR acetylation mimic mutants [AR lysine
630 to glutamine (AR K630Q/lysine 630 to threonine (AR
K630T)] (Figure 3B) was increased in the presence of
DHT compared to the wild-type AR.These
acetylation-mimicking mutations in prostate cancer cells
exhibited increased cell growth in vitro and showed
increased tumor growth in vivo, and these tumors were
resistant to the AR antagonist, flutamide [Fu et al., 2003].
Although these studies suggest that there is a link
between AR acetylation and prostate cancer, specific
experiments to test this have not yet been reported.
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occurs at lysine residues 630, 632, and 633 and is mediated by
interactions with coregulators with intrinsic histone acetyltransferase (HAT)
activity, such as coactivators p300, P/CAF and TIP60 (Tat-interactive
protein). (B) Acetylation mimicking mutants (K630Q/K630T) exhibited
increased cell growth in prostate cancer cell lines.
Estrogen receptor α
Clinical relevance of phosphorylated forms of
ERα in human breast cancer
The estrogen receptor α (ERα) status of breast tumors
has been used clinically since the late 1970s to identify
those patients most likely to gain benefit from endocrine
therapies. However, ERα status is an imperfect marker
of endocrine therapy response and a current research
priority is the search for more precise markers of
treatment response and outcome. ERα, similar to other
steroid hormone receptors, can be phosphorylated at
multiple sites within the protein [Murphy et al., 2011]
(Figure 1).
In addition to estrogenic ligands, ERα can be activated
in a ligand-independent fashion, often by signals
generated at the plasma membrane by growth factor
receptors [Lannigan, 2003].When it was found that ERα
could be directly phosphorylated by several kinases
activated by membrane growth factor receptor signaling
[Kato et al., 1995], the possibility arose of crosstalk
between ERα and growth factor receptor signaling, which
could underlie ligand-independent activation of ERα
signaling and the development of resistance to endocrine
therapies [Arpino et al., 2008]. Results from several cell
line and xenograft models supported this hypothesis
[Arpino et al., 2008].
One way to gain insights into the putative role of a gene
in human breast cancer in vivo is frequently obtained by
investigating relationships of gene expression in tumor
samples to known biomarkers of prognosis and treatment
response, and to clinical outcomes such as release free
survival (RFS) and overall survival (OS) in
retrospectively-collected patient cohorts.When antibodies
specific for phosphorylated amino acids within the ERα
became available, the opportunity arose to test
experimental hypotheses in human breast tumors in vivo.
Antibodies to p-S118 and p-S167 on ERα have been
commercially available since 2003. Our laboratory was
the first to determine expression of p-S118 - ERα in
multiple breast cancer cases stored in the Manitoba
Breast Tumor Bank (MBTB) [Skliris et al., 2009].
Subsequently, additional studies were published
demonstrating the expression of one or both of these
p-ERα sites by IHC in cohorts of breast tumor biopsy
samples [Holm et al., 2009; Jiang et al., 2007; Murphy et
al., 2004; Skliris et al., 2009].
More recently, detection of other phosphorylated sites on
ERα has been published by our laboratory and others
[Atsriku et al., 2009; Britton et al., 2008;Williams et al.,
2009]. In some of these studies, associations with other
histopathological markers, clinical outcome and specific
kinases were found [Jiang et al., 2007; Skliris et al., 2010].
Although sometimes contradictory results have been
found, some common themes have emerged, especially
with regard to p-S118 and p-S167, which have been the
major focus to date.
Firstly, and in contrast to what was expected, detection
of p-S118- and/or p-S167-ERα in breast tumors is
generally associated with features of an intact estrogen
responsive signaling pathway [Jiang et al., 2007; Murphy
et al., 2004] and therefore more differentiated phenotypes.
These data suggested that the detection of either p-S167-
and/or p-S118-ERα may be surrogate markers for tumors
that are more dependent on ERα signaling for growth,
and are therefore more likely to respond to tamoxifen
(Tam) therapy.
Indeed, a second emerging theme is that those patients
whose tumors express p-S118- and/or p-S167-ERα more
often have a better clinical outcome to Tam therapy in
retrospective studies [Jiang et al., 2007; Murphy et al.,
2004;Yamashita et al., 2005;Yamashita et al., 2008].
More recently, detection of p-S118-ERα in breast tumors
was also associated with a better clinical outcome to
aromatase inhibitors [Generali et al., 2009]. In our study,
we found that measurement of progesterone receptor
(PR), either by IHC or LBA (ligand binding assay) [Skliris
et al., 2009;Weitsman et al., 2006], was still a stronger
predictor of RFS and OS than the p-S118-ERα for
patients on tamoxifen. Interestingly, however, we also
found that addition of p-S118-ERα to PR further improved
the prediction of response to endocrine therapy [Murphy
et al., 2004]. Such data support combined use of
biologically-relevant markers for the improved prediction
of therapy response, at least with respect to endocrine
therapy.
Although some studies find a weak positive association
of ERBB2/HER2 expression and p-S118 [Jiang et al.,
2007;Yamashita et al., 2008], we and others have found
no significant differences in the expression of p-S118
and/or p-S167 in ER+ tumors that either overexpress or
do not express ERBB2/HER2 [Jiang et al., 2007;
Weitsman et al., 2006].
The data published so far therefore do not strongly
support the hypotheses that ligand-independent activation
of ERα by phosphorylation due to overexpression of
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of de novo tamoxifen and possibly aromatase inhibitor
resistance in human breast cancer in vivo.
More recently, antibodies to other phosphorylation sites
on ERα, i.e., p-S104/106, p-S282, p-S294, p-T311,
p-S559, have been validated for IHC of formalin-fixed
paraffin-embedded breast tumor tissues [Skliris et al.,
2009] and the results obtained support a third emerging
theme that multiple phosphorylated forms of ERα can be
detected in any one tumor sample [Jiang et al., 2007;
Skliris et al., 2009;Yamashita et al., 2008].The
relationship of these other phosphorylation sites to known
biomarkers and response to endocrine therapies is
currently unclear.
In contrast to the results for p-S118 and/or p-S167,
detection of p-S305 in ERα in breast tumors from
pre-menopausal women who had received tamoxifen for
2 years was associated with no benefit from tamoxifen
[Holm et al., 2009]. Furthermore, experimental studies
support a role for phosphorylation at S305 in tamoxifen
resistance [Michalides et al., 2004], suggesting that not
all types of phosphorylation of ERα predict a good
outcome to endocrine therapies.
It is interesting that those phosphorylation sites that are
so far associated with better clinical outcome to endocrine
therapies are located in the N-terminus of the protein and
those identified to be associated with poorer outcome
(S305, T311, and S559 [Skliris et al., 2010]), are located
in a region at the border of the hinge region and the ligand
binding domain.
Interestingly, S305 is adjacent to an acetylation site
(K303) that has been implicated in modulating sensitivity
to E2 [Fuqua et al., 2000] and regulating the efficiency of
S305 as a substrate for PKA [Cui et al., 2004]. Inhibition
of acetylation at this site by mutation of K303 to R resulted
in reduced sensitivity to tamoxifen [Giordano et al., 2010]
and aromatase inhibitors [Barone et al., 2010].There is
precedence for coupling regulation between
phosphorylation and acetylation in adjacent areas of
proteins and effects on protein function [Kramer et al.,
2009].
ERα acetylation and breast cancer
Acetylation of ERα requires the interaction of ERα with
coregulators, such as p300/CBP, that have intrinsic
histone acetyltransferase (HAT) activity [Wang et al.,
2001] and/or recruit HATs. ERα is selectively acetylated
on lysine residues 299, 302 and 303 by p300 within the
well-conserved hinge/ligand binding domain (Figure 4A)
[Wang et al., 2001].
The mutation of lysine residues 302 or 303 to arginine
(rendering these sites incapable of being acetylated)
(Figure 4B) resulted in hypersensitivity to estradiol that
led to increased estradiol-dependent activation of ERα,
suggesting that ERα acetylation normally suppresses
ligand sensitivity [Fuqua et al., 2000;Wang et al., 2001].
Additionally, independent clinical studies have identified
a Lys-to-Arg substitution at nucleotide 908 (referred to
as K303R) in 34% of atypical breast hyperplasia samples
[Conway et al., 2005; Fuqua et al., 2000; Herynk et al.,
2007]. A K303R mutation enhanced cellular proliferation
in response to low concentrations of estradiol, suggesting
the ERα K303R mutation provides a “gain of function”
mutation in human breast cancer.
Furthermore, Conway et. al. [Conway et al., 2005]
reported similar mutations in 5.7% of screened breast
tumors, with more frequent occurrences in high grade
breast tumors and in mixed lobular/ductal tumors,
compared with ductal carcinomas.
In another study, ~50% of breast cancer samples
contained K303R mutations [Herynk et al., 2007], and in
this cohort of patients, women over the age of 50 had
more frequent mutations when compared to lower age
groups (54.4% versus 37.5%). Moreover, a higher
frequency of mutation was found in lymph node positive
compared to negative tumors (70% versus 34.8%)
[Herynk et al., 2007].
Figure 4.  Acetylation of estrogen receptor α. (A) Acetylation of the
estrogen receptor α requires the interaction of the receptor and of
coregulators such as p300 that possess intrinsic histone acetyltransferase
(HAT) activity. (B) Mutation of lysine residues 302/303 to arginine,
rendering these sites incapable of being acetylated, resulted in
hypersensitivity to estradiol in breast cancer cell lines.
ERα sumoylation and breast cancer
Sumoylation of ERα occurs through the modification of
lysine residue(s) in the AF-1 domain [Choi et al., 2006].
Two ligand-dependent sumoylation sites, lysine 266 and
268 (K266 and K268), have been identified in the ERα
hinge region that can result in increased ERα target gene
expression in vitro (Figure 5A) [Sentis et al., 2005].The
hinge region of ERα is a specific target of SUMO-E3
ligases (catalyzes the covalent attachment of a SUMO),
PIAS1 (Protein inhibitor of Activated STAT), and PIAS3
(Figure 5A) [Karamouzis et al., 2008]. An increase in
expression of PIAS3 has been documented in breast
cancer [Wang and Banerjee, 2004].
Future clinical studies are needed to determine whether
ERα sumoylation in breast cancer has prognostic value
or serves as a predictor for response to endocrine
therapy.
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(A) Sumoylation of ERα occurs at lysine residues 266 and 268 (K266 and
K268). (B) Unstimulated estrogen receptor is ubiquitinated and degraded
by carboxyl terminus of Hsp70-interacting protein (CHIP), an ubiquitin E3
ligase. Fulvestrant (ICI 182,780), a pure anti-estrogen, utilizes the
ubiquitination mechanism to induce proteasome-dependent degradation
of ERα.
Ubiquitination and ERα
The stability of ERα is affected differentially by agonists,
antagonists, and selective estrogen receptor modulators
[Reid et al., 2002;Wijayaratne and McDonnell, 2001].
Both ligand-stimulated, as well as unstimulated ERα,
have been shown to be ubiquitinated and degraded by
the proteasomal system (Figure 5B) [Tateishi et al., 2004].
Studies performed by the Gannon and O'Malley
laboratories showed that the proteasomal degradation of
transcription factors is a necessary step in the regulation
of target gene transcription, possibly by enabling the
sequential formation of protein complexes at the promoter
region [Lonard et al., 2000; Reid et al., 2002]. Stable,
unliganded ERα, which has a half-life of up to 5 days
[Nirmala and Thampan, 1995], is ubiquitinated and
degraded by carboxyl terminus of Hsp70-interacting
protein (CHIP), a ubiquitin E3 ligase [Fan et al., 2005].
Binding of estradiol to ERα dramatically reduced the
half-life of ERα to 3-5 h [Nirmala and Thampan, 1995].
As a result of the recruitment of proteins implicated in the
proteasome system, ERα is degraded.The proteins that
are involved in the ubiquitination are ubiquitin ligases
E6-AP, MDM2, SUG1, and the coactivators SRC-1 and
SRC-3 (see review by [Le Romancer et al., 2011]).
Fulvestrant (ICI 182,780), a pure anti-estrogen that is
currently used in adjuvant therapies for breast cancer,
utilizes the ubiquitination mechanism to induce
proteasome-dependent degradation of ERα [Lanvin et
al., 2007]. Degradation of ERα induced by fulvestrant is
independent of its transcriptional activity and new protein
synthesis [Marsaud et al., 2003;Wijayaratne and
McDonnell, 2001].
Glucocorticoid receptor
Anti-inflammatory effect of GR
Treatment with glucocorticoids is one of the most effective
therapies for many chronic inflammatory diseases such
as asthma, rheumatoid arthritis, and inflammatory bowel
disease [Adcock and Ito, 2000]. Glucocorticoids bind to
the cytosolic GR, which then translocates to the nucleus.
GR can induce transcription of anti-inflammatory genes,
such as secretory leukocyte proteinase inhibitor (SLPI)
[Abbinante-Nissen et al., 1995] and mitogen-activated
kinase phosphatase-1 (MKP-1) [Lasa et al., 2002], or
inhibit transcription of pro-inflammatory genes such as
interleukin-6 (IL-6) (Figure 6) [Ray et al., 1994]. GR also
reduces inflammatory gene expression induced by NF-κB
(Nuclear Factor-κB), AP-1 (Activator Protein-1) or via
trans-repression through direct protein interaction with
these proteins (reviewed in [De Bosscher et al., 2003]).
Figure 6.  GR regulation of inflammatory genes. Upon ligand
binding, the GR translocates to the nucleus, is acetylated by HATs, and
binds to Glucocorticoid Response Elements (GRE) to induce transcription
of anti-inflammatory genes.The liganded GR can also functionally repress
NF-κB-mediated pro-inflammatory genes.
GR phosphorylation in inflammation and asthma
in humans
As previously stated, glucocorticoids are used as primary
treatment options for many inflammatory diseases;
however, some patients are unresponsive to these
treatments due to glucocorticoid resistance. Among the
mechanisms for this resistance is decreased
glucocorticoid signaling by changes in GR
phosphorylation [Bloom, 2004; Li et al., 2004;Tsitoura
and Rothman, 2004]. GR is phosphorylated by
cyclin-dependent kinases, MAPK and casein kinase II at
5 serine residues, S113, S141, S203, S211 and S226
[Ismaili and Garabedian, 2004]. p38 MAP kinase has
been shown to be active in alveolar macrophages of
asthmatic patients who showed poor response to
glucocorticoids in comparison to patients with a normal
response [Bhavsar et al., 2008].The phosphorylation of
GR by p38 MAPK subsequently affects GR function,
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treatment.The serine residue of GR phosphorylated by
p38 MAP kinase has yet to be elucidated; it is plausible
that S211 or S226 could be phosphorylated [Irusen et al.,
2002; Miller et al., 2005; Szatmary et al., 2004]. Use of
p38 MAPK inhibitors increased the anti-inflammatory
effects of glucocorticoids and reestablished the beneficial
effects of glucocorticoids in glucocorticoid-resistant
patients suffering from asthma [Irusen et al., 2002].
Studies have also shown that a large proportion of
patients with glucocorticoid-resistant asthma showed
reduced nuclear translocation of GR and DNA binding in
PBMCs (Peripheral Blood Mononuclear Cells) after
glucocorticoid exposure, and this could be due to changes
in glucocorticoid receptor phosphorylation [Matthews et
al., 2004; Szatmary et al., 2004].
Together, these studies suggest GR phosphorylation by
p38 MAPK is one of the mechanisms leading to
glucocorticoid resistance. Clinical studies are needed to
determine if the clinical benefit of p38 MAPK inhibitors in
asthmatic patients is related to changes in GR
phosphorylation.
GR acetylation increases glucocorticoid
insensitivity
Lysine 494 and 495 are the two ligand-dependent
acetylation sites identified in GR [Ito et al., 2006]. GR
binds to NF-κB and represses inflammatory gene
transcription by NF-κB. Acetylated GR loses its affinity
for NF-κB and therefore cannot repress inflammatory
gene transcription induced by NF-κB (Figure 6). Histone
deacetylase 2 (HDAC2) deacetylates GR, thereby
enabling the association of GR with NF-κB and
attenuation of pro-inflammatory gene transcription.
Silencing HDAC2 by RNA interference resulted in reduced
corticosteroid-sensitivity in primary alveolar macrophages
and human lung epithelial cell lines.
Overexpression of HDAC2 in glucocorticoid-resistant
alveolar macrophages from patients with COPD (chronic
obstructive pulmonary disease) resulted in restoration of
corticosteroid-sensitivity [Ito et al., 2006].Taken together,
acetylated GR could not inhibit NF-κB-dependent gene
transcription, due to the reduced binding to NF-κB. It is
plausible that hyperacetylation of GR, due to absence of
HDAC2, may lead to glucocorticoid insensitivity.
Peroxisome proliferator-activated
receptors
Peroxisome proliferator-activated receptors (PPAR) play
an important role in the regulation of lipid homeostasis,
energy metabolism, inflammatory responses and the
induction of apoptosis [Issemann and Green, 1990; Rosen
and Spiegelman, 2006].The PPAR family consists of
three subtypes, PPARα, PPARδ and PPARγ, encoded
by separate genes, and among these subtypes, PPARγ
has been studied extensively.The PPARs form
heterodimers with the retinoid-X receptor (RXR), which
then binds to response elements (PPRE) in the regulatory
regions of target genes [Mangelsdorf and Evans, 1995].
PPAR phosphorylation and insulin resistance
and obesity
Adipocyte differentiation is an important component of
obesity and other metabolic diseases and this process is
inhibited by mitogens and oncogenes. Several growth
factors that inhibit fat cell differentiation cause
MAPK-mediated phosphorylation of PPARγ and reduce
its transcriptional activity. Growth factor-induced
phosphorylation of S112 of PPAR-γ repressed its
transcriptional and adipogenic functions [van Beekum et
al., 2009], whereas expression of PPARγ with a
non-phosphorylatable mutation at serine-112 (S112)
yielded cells with increased sensitivity to ligand-induced
adipogenesis and resistance to inhibition of differentiation
by mitogens, as compared to cells expressing wild type
PPARγ (Figure 1) [Hu et al., 1996; Iwata et al., 2001;
Ristow et al., 1998]. Homozygous PPARγ S112A knock-in
mice did not develop insulin resistance and exhibited no
change in body weight when fed a high fat diet [Rangwala
et al., 2003].These findings indicate that phosphorylation
of PPARγ by growth factors is a major regulator of the
balance between cell growth and differentiation in the
adipose tissue.
A mutation of proline 115 to glutamine (P115Q) in PPARγ
prevents phosphorylation at S112 in PPARγ P115Q [van
Beekum et al., 2009], would remove a canonical Ser-Pro
phosphorylation motif at S112 and consequently prevent
phosphorylation by Ser-Pro directed kinases. It is likely
that the P115Q mutation and loss of S112
phosphorylation could lead to an increase in adipogenesis
and possibly obesity and insulin resistance in humans.
A heterozygous P115Q mutation was reported in four
obese individuals in a cohort of 358 [van Beekum et al.,
2009].Three of these obese individuals (BMI 37.9-47.3)
were diagnosed with type 2 diabetes. Ristow et al.
reported the same mutation associated with obesity
without type 2 diabetes [Ristow et al., 1998]. Blüher and
Paschke [Bluher and Paschke, 2003] reported an
individual with the P115Q mutation who exhibited high
fasting insulin levels and profound insulin resistance.
However, a German cohort of 85 [Hamer et al., 2002]
and 67 [Evans et al., 2000] did not find an association of
P115Q with obesity. Similarly, in a French cohort of 626,
P115Q was not associated with obesity [Clement et al.,
2000].
Additional studies on homozygous and heterozygous
S112A and P115Q PPARγ mutations in different genetic
backgrounds and under different dietary regimes will help
to understand the role of PPARγ phosphorylation in
obesity.
Cdk5-mediated phosphorylation of PPARγ may
be involved in the pathogenesis of
insulin-resistance
Cdk5 has been shown to phosphorylate PPARγ at Serine
273 (S273). Phosphorylation of S273 by Cdk5 did not
impact the general transcriptional activity of PPARγ, but
did alter the expression of specific genes such as
adiponectin (insulin sensitizing hormone) [Choi et al.,
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been linked to obesity in mice induced by high-fat diet
[Rangwala et al., 2003]. Anti-diabetic PPARγ ligands such
as rosiglitazone and MRL24 directly inhibited S273
phosphorylation by Cdk5 without affecting S112
phosphorylation, resulting in restoration of a non-diabetic
pattern of gene expression [Choi et al., 2010]. Moreover,
inhibition of S273 phosphorylation by rosiglitazone in
humans was associated with the anti-diabetic effects of
the drug [Choi et al., 2010]. Further studies relating
PPARγ phosphorylation to diabetes may offer the
opportunity for development of improved next-generation
anti-diabetic drugs.
Sumoylation of PPARγ results in transrepression
of inflammatory genes
PPARγ has been demonstrated to have an
anti-inflammatory effect and PPARγ ligands have been
used in clinical trials for patients with inflammatory
diseases [Giaginis et al., 2009; Spears et al., 2006].The
mechanism for the anti-inflammatory effect of PPARγ
ligands may include sumoylation of the receptor (Figure
7). Expressed in macrophages, PPARγ functions to
negatively regulate macrophage activation by repressing
a subset of AP1 and NF-κB-dependent genes, ultimately
repressing macrophage inflammatory genes [Jennewein
et al., 2008; Pascual et al., 2005]. One mechanism
regulating PPARγ inhibition of inflammatory genes is
sumoylation of PPARγ at its consensus sumoylation sites,
lysines 77 and 365 [Pascual et al., 2005].The initial step
in the sumoylation pathway involves ligand-dependent
sumoylation of the PPARγ ligand-binding domain, that
targets PPARγ for binding to nuclear receptor corepressor
(NCoR)/histone deacetylase-3 (HDAC3) complexes at
inflammatory gene promoters [Pascual et al., 2005].This
in turn, prevents recruitment of the ubiquitinylation/19S
proteasome machinery that normally mediates the
signal-dependent removal of corepressor complexes
required for gene activation [Pascual et al., 2005]. As a
result, NCoR complexes are not cleared from the
promoter and target genes are maintained in a repressed
state [Pascual et al., 2005]. Recent studies have
demonstrated that PPARγ inhibits inflammatory gene
expression in activated macrophages by the
NCoR/sumoylation-dependent pathway [Ghisletti et al.,
2007; Jennewein et al., 2008; Pascual et al., 2007].
Figure 7.  Sumoylation of PPARγ and transcriptional repression of
inflammatory genes. Sumoylation of PPARγ promotes interaction with
a transcriptional repression complex at NF-κB gene promoters preventing
release and turnover of the repression complex, thereby maintaining
repression of inflammatory genes.
Ubiquitination and PPARγ
The PPAR-γ protein has a short half-life of 2 hours
[Christianson et al., 2008;Waite et al., 2001] and was
found to be polyubiquitinated and degraded by the
proteasome [Floyd and Stephens, 2002; Hauser et al.,
2000]. Ubiquitination of PPAR-γ and degradation are
strongly linked to ligand binding and activation, as TZDs
(e.g., troglitazone, rosiglitazone) accelerated these
processes [Floyd and Stephens, 2002; Hauser et al.,
2000].The exposure of adipocytes to the cytokine
interferon-γ elicited by infiltrating interferon-γ-producing
lymphocytes into adipose tissue [Kintscher et al., 2008],
was also found to increase ubiquitination and degradation
of PPAR-γ [Floyd and Stephens, 2002], indicating that
ubiquitination can also be regulated by external stimuli.
Studies by [Kubota et al., 1999; Miles et al., 2000] have
shown that reduced PPARγ expression in mice (PPARγ
+/-)
is associated with resistance to weight gain along with
protection from the insulin resistance that typically
accompanies weight gain. In addition, genetic evidence
indicates that decreased PPARγ activity may protect
against insulin resistance in humans [Deeb et al., 1998].
Conversely, PPARγ is required for the formation of fat
cells, and a lack of adipose cells is associated with insulin
resistance and hyperglycemia [Willson et al., 2001]. All
of these studies indicate that a careful balance between
PPARγ expression and activity levels must be maintained
to avoid development of diseases such as type II diabetes
and obesity.The ubiquitin-proteasome pathway plays an
important role in the regulation of PPARγ levels in
adipocytes [Hauser et al., 2000].
Interactions of PTM in human disease
A complex network of signaling pathways does not rely
only on phosphorylation or acetylation or any single PTM,
rather they are likely controlled by the coordinated actions
of phosphorylation, acetylation and a myriad of
combinations of PTMs. One or more PTMs, or the same
PTM at different residues, can occur on a protein. Multiple
PTMs may occur simultaneously or sequentially that
would be necessary for the distinct outcome of signaling
pathways. Although the implications of PTMs such as
phosphorylation and acetylation have been relatively well
documented, interactions among these PTMs remain
fertile ground for future investigations. Both positive and
negative crosstalk occurs among NRs. In positive
crosstalk, the first PTM serves as a signal for the addition
or removal of another PTM, or for the recognition by a
protein that induces a second modification.
Phosphorylation-dependent ubiquitination and
phosphorylation-dependent sumoylation are good
examples. It is intriguing to note that phosphorylation of
NRs has been linked to ubiquitination and protein
turnover. A direct link between ERα phosphorylation and
ubiquitination has been demonstrated by Alarid and
colleagues [Valley et al., 2005]. Phosphorylation of ERα
at S118 plays a role in estradiol-mediated ERα
degradation by regulating recruitment of factors mediating
ubiquitination [Valley et al., 2005]. Phosphorylation of
ERα by P21 activated Kinase (PAK1) at ERα S305
influences the activation status of ER S118 and the
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functional S118.Transgenic mice expressing active PAK1
exhibited both activated ERα-305 and ERα-S118
phosphorylation (for a review of crosstalk of ER PTMs,
see [Le Romancer et al., 2011]). Phosphorylation at AR
S210 and S790 by Akt has been shown to promote AR
ubiquitination and its subsequent proteosomal
degradation [Lin et al., 2002]. Mutation at phosphorylation
sites of GR (Serine 122, 150, 212, 220, 234, 315, 412,
and threonine 159 to alanine) inhibited ligand-dependent
GR degradation and consequently, GR-mediated
transcriptional activity [Wallace and Cidlowski, 2001;
Webster et al., 1997], which indicated yet another NR
ubiquitination that is phosphorylation-dependent. A
hypo-phosphorylated form of PPARγ that increased
transcriptional activity was degraded faster compared to
a phosphorylated form (S112), indicating that in this NR,
phosphorylation inhibited ubiquitination and protein
degradation [Floyd and Stephens, 2002]. Additionally,
phosphorylation of PPARγ at S112 stimulated sumoylation
at K107 and this was shown to reduce the ability of
PPARγ to activate the adipogenic gene expression
pathway.
In negative crosstalk, there is direct competition for
modification of a single amino acid residue in a protein,
or one modification masks the recognition site for the
second PTM. In ERα, lysine residue K302 can be
modified by ubiquitination, sumoylation, acetylation, or
methylation. Since lysine is the target for ubiquitin
enzymes, acetylation and methylation status might affect
the protein turnover. ERα phosphorylation at S305 has
been shown to inhibit acetylation of ERα at K303 [Cui et
al., 2004]. A phosphomimicking mutation at S305 to E305
blocked K303 acetylation and produced an enhanced
transcriptional response. However, all these interactions
among different PTMs have yet to be analyzed in clinical
studies.
It is important to note the caveats associated with
evaluation of PTMs in nuclear receptors. PTMs are both
dynamic and reversible processes that can be rapidly
altered in response to changes in the cellular and
environmental conditions that occur following tissue
excision, including time to preserve or fix harvested tissue
samples from patient biopsies or resection samples. It
should be noted that the quality of the tissue and labile
modifications, most notably phosphorylation, can be
dramatically affected by pre-analytic variables (i.e.,
ischemic time, hypoxia, temperature or fixation time,
exposure of patients to anesthetics and other drugs
[Pinhel et al., 2010; Siddiqui and Rimm, 2010]).
Alterations in phosphorylation and sumoylation status
can occur as a result of ischemic and hypoxic conditions
due to the change in the activities of endogenous
phosphatases, kinases and sumo ligases and proteases
during sample collection [Ahmed and Gardiner, 2011;
Cimarosti et al., 2008]. Developing common tissue
procurement guidelines to collect and store the clinical
samples for the analysis of protein PTMs will avoid the
alteration in the PTMs by other factors. All these caveats
should be accommodated for when evaluating and
interpreting results of PTMs in NRs from clinical samples.
Summary and future perspectives
This review has summarized basic and clinical research
studies that link specific NR PTMs to a wide range of
human diseases. In many cases, perturbation of a PTM
can be associated with a change in receptor
transcriptional function that underlies a pathological
consequence in a tissue or organ system. Ongoing clinical
studies will likely identify additional NR PTMs that are
associated with disease progression and resistance to
standard of care therapies that target NRs. Additionally,
the development of more stringent in vivo models will also
aid in better understanding of the mechanisms by which
NR PTMs impact physiological processes and disease.
To date, much of the in vivo research on NR PTMs has
been conducted using transgenic mouse models.While
these models have provided valuable insight into the
functioning of PTMs, the creation of mouse models in
which specific PTMs are altered in the endogenous NR
will be crucial. Examination of the effects of PTMs on
gene expression and chromatin interaction is another
important avenue of research. As previously mentioned,
the vast majority of NR PTMs ultimately affect
transcriptional activity and determining the effect of PTMs
on systemic gene expression will not only provide insight
into the global effects of aberrant PTMs associated with
disease, but can also indicate potential gene targets for
development of targeted therapeutics. Finally, research
examining the role of PTMs of NR in disease must also
evaluate the actual addition of PTMs and determining
what role PTM turnover plays in disease
pathophysiological progression. Current research has
focused on PTMs that result in the addition of specific
phosphate groups, ubiquitin tags, sumo proteins, etc.
However, there appears to be a dearth of information
regarding PTM turnover. As has been elegantly
demonstrated for ERα phosphorylation in breast cancer,
future studies will firmly establish NR PTMs as valuable
surrogate measures of NR function, that may also be
used as biomarkers for disease progression, as well as
predictive markers for patient response to NR-directed
therapies.
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